200,000+ products from a single source!
sales@angenechem.com
204460-24-2 | 1(6H)-Pyrimidineacetamide, N-[2,3-dioxo-1-(phenylmethyl)-6-(2-pyridinyloxy)hexyl]-5-(formylamino)-6-oxo-2-phenyl-
CAS No: 204460-24-2 Catalog No: AG0029IN MDL No:
Product Description
Catalog Number:
AG0029IN
Chemical Name:
1(6H)-Pyrimidineacetamide, N-[2,3-dioxo-1-(phenylmethyl)-6-(2-pyridinyloxy)hexyl]-5-(formylamino)-6-oxo-2-phenyl-
CAS Number:
204460-24-2
Molecular Formula:
C31H29N5O6
Molecular Weight:
567.5919
IUPAC Name:
N-(3,4-dioxo-1-phenyl-7-pyridin-2-yloxyheptan-2-yl)-2-(5-formamido-6-oxo-2-phenylpyrimidin-1-yl)acetamide
InChI:
InChI=1S/C31H29N5O6/c37-21-34-25-19-33-30(23-12-5-2-6-13-23)36(31(25)41)20-27(39)35-24(18-22-10-3-1-4-11-22)29(40)26(38)14-9-17-42-28-15-7-8-16-32-28/h1-8,10-13,15-16,19,21,24H,9,14,17-18,20H2,(H,34,37)(H,35,39)
InChI Key:
QOANBAXBOLUAFA-UHFFFAOYSA-N
SMILES:
O=CNc1cnc(n(c1=O)CC(=O)NC(C(=O)C(=O)CCCOc1ccccn1)Cc1ccccc1)c1ccccc1
Properties
Complexity:
1030
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
567.212g/mol
Formal Charge:
0
Heavy Atom Count:
42
Hydrogen Bond Acceptor Count:
8
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
567.602g/mol
Monoisotopic Mass:
567.212g/mol
Rotatable Bond Count:
14
Topological Polar Surface Area:
147A^2
Undefined Atom Stereocenter Count:
1
Undefined Bond Stereocenter Count:
0
XLogP3:
2.5
Literature
| Title | Journal |
|---|---|
| Chymase plays an important role in left ventricular remodeling induced by intermittent hypoxia in mice. | Hypertension (Dallas, Tex. : 1979) 20090701 |
| Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. | Atherosclerosis 20090601 |
| Mast cells: pivotal players in cardiovascular diseases. | Current cardiology reviews 20080801 |
| Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis. | The Journal of pharmacology and experimental therapeutics 20080201 |
| Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. | Hypertension research : official journal of the Japanese Society of Hypertension 20060101 |
| Effect of chymase inhibition on the arteriovenous fistula stenosis in dogs. | Journal of the American Society of Nephrology : JASN 20050401 |
| A specific chymase inhibitor, NK3201, suppresses bleomycin-induced pulmonary fibrosis in hamsters. | European journal of pharmacology 20040616 |
| A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[3,4-dioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl]acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. | The Journal of pharmacology and experimental therapeutics 20040601 |
| Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. | Cardiovascular research 20031101 |
| Will chymase inhibitors be the next major development for the treatment of cardiovascular disorders? | Expert opinion on investigational drugs 20030801 |
| A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[,4-dioxo-1-phenyl-7-(2-pyridyloxy)]2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. | The Journal of pharmacology and experimental therapeutics 20030201 |
| Application of a chymase inhibitor, NK3201, for prevention of vascular proliferation. | Cardiovascular drug reviews 20030101 |
| Development of the chymase inhibitor as an anti-tissue-remodeling drug: myocardial infarction and some other possibilities. | Japanese journal of pharmacology 20021101 |
| Oral administration of a novel chymase inhibitor, NK3201, prevents peritoneal adhesion formation in hamsters. | Japanese journal of pharmacology 20020901 |
| Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. | Life sciences 20010831 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.